A single bacterial lineage of Acinetobacter baumannii now accounts for roughly 70 percent of clinical isolates worldwide, and a genomic analysis spanning more than 15,000 samples has reconstructed how it got there. The pathogen’s rise did not happen overnight. It unfolded across roughly eight decades through a series of genetic gains that made the organism progressively harder to kill with antibiotics, turning it into one of the most dangerous infections a hospitalized patient can face.
How one clone displaced its rivals in hospitals worldwide
Carbapenem-resistant A. baumannii, often shortened to CRAB, ranks among the most urgent drug-resistant threats in health care settings. Patients in intensive care units, burn wards, and ventilator bays are especially vulnerable because the bacterium thrives on medical surfaces and shrugs off most available drugs. A 2023 investigation in a leading journal described CRAB as a major global pathogen with very few effective treatments, a gap that has persisted for decades while new antibiotic classes targeting gram-negative bacteria remained scarce.
What the latest genomic reconstruction adds is a timeline. Researchers analyzed more than 15,000 A. baumannii genomes and identified an epidemic super-lineage, international clone 2 (IC2), that now dominates clinical collections on every inhabited continent. That reconstruction, published in a large-scale genomic study, traces IC2’s stepwise evolution across approximately eight decades, showing that its success was not the result of a single lucky mutation. Instead, the lineage accumulated resistance tools in waves, each one giving it a sharper edge in environments saturated with antibiotics.
The hypothesis that best fits the data centers on how IC2 handled one gene in particular: blaOXA-23, which encodes an enzyme that breaks down carbapenem antibiotics. Rather than picking up the gene once and stopping, IC2 strains repeatedly acquired blaOXA-23 through mobile genetic elements called transposons, including composite structures such as Tn2006 and Tn2009. Work summarized in a detailed resistance review shows that multiplication of blaOXA-23 is common in clinical A. baumannii and that the gene is consistently associated with these specific transposon architectures. Each additional copy or insertion event did not necessarily raise the minimum drug concentration needed to kill the bacterium in a test tube, but the repeated genetic rearrangements appear to have given IC2 a survival advantage in real hospital wards where antibiotic pressure is constant, overlapping, and often poorly coordinated.
By repeatedly mobilizing blaOXA-23, IC2 effectively turned carbapenems-the last-resort drugs for many severe infections-into unreliable options. Once those therapies falter, clinicians are left with older, more toxic antibiotics such as colistin, sometimes in combination regimens with uncertain benefit. The genomic evidence suggests that this erosion of reliable treatment did not occur as a single tipping point but as an incremental tightening of the screw, with each new transposon insertion making it a little more likely that IC2 would survive an antibiotic course that killed its competitors.
Decades of archived bacteria fill the genomic gap
A key piece of the puzzle came from historical isolates. Researchers at the Quadram Institute sequenced 226 A. baumannii samples collected between the 1970s and the early 2000s using long-read Oxford Nanopore technology, then merged those sequences with more than 1,000 modern genomes. That combined dataset allowed the team to watch IC2 “creep into dominance” over time, displacing an earlier lineage known as global clone 1 (GC1). Separate genomic work on GC1 had already shown that this predecessor lineage acquired its own resistance package, the AbaR resistance island, in the late 1970s. That earlier study, covering five decades of GC1 evolution, demonstrated that multi-decade genomic reconstruction of A. baumannii was feasible and that major resistance jumps could be dated with reasonable precision.
The combined picture suggests a competitive relay. GC1 gained an early advantage through AbaR, which carried multiple resistance genes on a single mobile element and allowed the lineage to withstand a broad panel of antibiotics that were heavily used in hospitals at the time. But IC2 eventually overtook it by layering on carbapenem resistance through blaOXA-23 transposons in a way that proved more durable across diverse hospital environments. Large-scale surveys of carbapenem-resistant A. baumannii genomes consistently find that a high proportion carry oxa23, making it the dominant carbapenemase in the species globally and reinforcing the idea that IC2’s particular strategy for capturing and amplifying this gene was decisive.
Long-read sequencing played a crucial role in clarifying that strategy. Short-read methods often struggle to assemble repetitive regions and mobile elements, leaving the exact structure of resistance islands ambiguous. By contrast, the Nanopore-based assemblies in the historical dataset were able to resolve entire transposons and their chromosomal neighborhoods, making it clear when blaOXA-23 was hopping between plasmids and chromosomes or inserting into new genomic contexts. That structural resolution underpins the argument that IC2’s rise was driven not only by which genes it carried, but also by where and how often those genes were mobilized.
The public health implications are immediate. The CDC has reported a sharp rise in dangerous drug-resistant bacteria across U.S. health care facilities, and A. baumannii is a recurring concern in those summaries. The same mobile genetic mechanisms documented in these genomic studies-transposons, resistance islands, and plasmid exchange-are therefore not historical curiosities. They are active drivers of mortality risk in hospitals right now, shaping which infections respond to treatment and which spiral into sepsis despite aggressive therapy.
Gaps in the IC2 timeline and what to watch next
For all the detail the genomic record provides, several questions remain open. The 226 historical isolates that anchor the pre-2000 portion of the timeline lack complete patient-level metadata such as admission dates, ward movements, comorbidities, and clinical outcomes. Without that information, researchers can show that IC2 spread and displaced its rivals, but they cannot directly quantify how many infections, ventilator-associated pneumonias, or deaths it caused during its ascent. No published dataset yet ties IC2-specific prevalence to U.S. hospital incidence figures, and the CDC’s reporting on drug-resistant bacteria does not break out transmission dynamics by clone type, making it difficult to translate genomic dominance into precise burden estimates.
The precise geographic route by which Tn2006 and its blaOXA-23 cargo moved between continents during the 1980s and 1990s also remains unclear. Genomic phylogenies can estimate when branching events occurred and infer that certain lineages likely emerged in particular regions, but they cannot confirm which hospitals, cities, or countries served as the main hubs of dissemination. Sparse sampling from low- and middle-income regions further blurs the picture, raising the possibility that important early steps in IC2’s expansion took place in settings that were not sequencing their isolates at the time.
Another unresolved issue is how much fitness cost IC2 paid for its resistance arsenal and how it compensated. Carrying multiple transposons and resistance islands can slow bacterial growth in the absence of antibiotics, yet IC2 has persisted even in wards where stewardship programs reduced carbapenem use. One hypothesis is that compensatory mutations elsewhere in the genome restored growth rates while preserving resistance, but the specific pathways involved have not been fully mapped.
Looking ahead, researchers are watching several trends. First, there is concern that IC2 could stack additional resistance determinants on top of blaOXA-23, including genes that blunt the activity of last-line drugs such as colistin or newer β-lactam/β-lactamase inhibitor combinations. Second, the same mobile elements that carried blaOXA-23 could, in principle, shuttle novel resistance genes into IC2 from other gram-negative species circulating in hospitals, accelerating its adaptation yet again. Finally, the success of IC2 raises the question of whether a successor lineage-equipped with an even more formidable resistance toolkit-might already be emerging in under-sampled regions.
For infection-control teams, the message is twofold. Surveillance needs to move beyond species-level identification toward routine genomic typing that can distinguish IC2 and track its sublineages. And antibiotic policies must account for the evolutionary reality that every additional course of carbapenems in an ICU does not just select for “resistance in general” but can actively sculpt the genome of dominant clones like IC2, favoring those variants that are best at capturing and rearranging resistance genes. The eight-decade story reconstructed from A. baumannii’s DNA is a reminder that hospital practices today will shape the pathogens that dominate wards a generation from now.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
